Patents by Inventor Konstantin Taganov

Konstantin Taganov has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20090203136
    Abstract: The present disclosure relates to the finding that microRNA-146 plays a role in modulating the development and function of the immune system. Immune cell development and function can be modulated by delivery of microRNA-146 (miR-146) or antisense miR-146 to target immune cells or precursor cells. For example, in some embodiments, activity and/or proliferation of certain immune cells is regulated by administering miR-146 oligonucleotides or anti-miR-146 oligonucleotides. In other embodiments, pro-inflammatory cytokine expression in immune cells is regulated by administering a miR-146 oligonucleotide or anti-miR-146. In further embodiments, methods of regulating macrophage activity using antisense miR-146 are provided. Additional methods and compositions for regulating immune system function and development using miR-146 are disclosed.
    Type: Application
    Filed: December 17, 2008
    Publication date: August 13, 2009
    Inventors: David Baltimore, Mark Boldin, Konstantin Taganov
  • Publication number: 20080300211
    Abstract: The present disclosure relates to the finding that microRNA-155 plays a role in inflammation, hematopoiesis and myeloproliferation, and that dysregulation of microRNA-155 expression is associated with particular myeloproliferative disorders. Disclosed herein are methods and compositions for diagnosing and treating disorders, including inflammation and myeloproliferation, modulating the levels of expression of one or more genes selected from the group consisting of Cutl1, Arnt1, Picalm, Jarid2, PU.1, Csf1r, HIF1?, Sla, Cepb?, and Bach1, and the like.
    Type: Application
    Filed: May 16, 2008
    Publication date: December 4, 2008
    Inventors: David Baltimore, Ryan O'Connell, Konstantin Taganov, Mark Boldin
  • Publication number: 20070232553
    Abstract: The present disclosure relates to the finding that microRNA-146 plays a role modulating the innate immune response. Innate immunity receptor signaling can be modulated by delivery of microRNA-146 (miR-146) or antisense miR-146 to target immune cells. In some embodiments, IL-1 receptor associated kinase 1 (IRAK1) and TNF receptor associated factor 6 (TRAF6) expression levels are downregulated in a target cell by administering a miR-146 oligonucleotide. Modulation of the innate immune system through miR-146 can be used to treat a variety of diseases and disorders associated with activation of the innate immune system, such as sepsis and Crohn's disease.
    Type: Application
    Filed: March 22, 2007
    Publication date: October 4, 2007
    Applicant: California Institute of Technology
    Inventors: David Baltimore, Mark Boldin, Konstantin Taganov